OncoMatch/Clinical Trials/NCT06112704
HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors
Is NCT06112704 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies HS-20093 for advanced solid tumor.
Treatment: HS-20093 — HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: B7-H3 targeted therapy
Previous or current treatment with B7-H3 targeted therapy
Cannot have received: cytotoxic chemotherapy
Exception: within 14 days prior to the first scheduled dose of HS-20093
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Cannot have received: investigational agent
Exception: within 14 days prior to the first scheduled dose of HS-20093
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Cannot have received: anticancer drug
Exception: within 14 days prior to the first scheduled dose of HS-20093
Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
Cannot have received: monoclonal antibody
Exception: within 28 days prior to the first scheduled dose of HS-20093
Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
Cannot have received: radiation therapy
Exception: local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
Cannot have received: surgery
Exception: major surgery within 4 weeks prior to the first scheduled dose of HS-20093
Major surgery within 4 weeks prior to the first scheduled dose of HS-20093
Lab requirements
Blood counts
Inadequate bone marrow reserve or organ dysfunction [excluded]
Kidney function
Inadequate bone marrow reserve or organ dysfunction [excluded]
Liver function
Inadequate bone marrow reserve or organ dysfunction [excluded]
Cardiac function
Evidence of cardiovascular risk [excluded]
Inadequate bone marrow reserve or organ dysfunction. Evidence of cardiovascular risk
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06112704 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior B7-H3 targeted therapy, cytotoxic chemotherapy, investigational agent disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify